article thumbnail

Exploring alternatives to animal testing in drug discovery

Drug Target Review

Animal testing plays a significant role in pre-clinical research and therefore requires the use of millions of animals. million scientific procedures involving live animals were carried out in 2020. million scientific procedures involving live animals were carried out in 2020. In Britain, 2.88 In Britain, 2.88

article thumbnail

Separating the Hype from the Hyperbole Surrounding FDORA’s Alternatives to Animal Testing under the FD&C Act

FDA Law Blog: Drug Discovery

While this hype may be warranted in some respects—a 60-year old legal provision has now been amended to acknowledge that the science of drug development is advancing—the change is mostly symbolic and is likely to take many years before we see it have a measurable impact. 42 U.S.C. § 262(k)(2)(A)(i)(I).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

4 ways ex vivo models offer Pharma better alternatives to animal testing

Reprocell

Pharma companies are legally required to test novel drugs in animal models before beginning human trials. And while animal testing has progressed thousands of therapeutics that we use today, it is not without its experimental and ethical downfalls.

article thumbnail

Increasing the probability of technical success in drug development using AI and patient heterogeneity

Predictive Oncology

Most drug failures occur in Phase II and Phase III clinical trials when drugs move from immortalized cell lines and animal testing to human patients. By combining these two assets, this offering represents an opportunity to de-risk drug discovery and accelerate pipeline development.

article thumbnail

In Silico for Drug Discovery

biobide

The in silico method represents an increasing role in drug discovery as technology becomes more sophisticated. It is fast becoming a cost-effective and efficient alternative to animal testing. It can be used in all stages of drug discovery, from screening to pre-clinical trials and greatly reduces drug development time.

article thumbnail

Streamlining the path from lab to market with 3D bioprinting

Drug Target Review

How do recent advancements in bioprinting technology promise to revolutionise the traditional drug development process, in terms of cost and timeline? By enabling a more direct assessment of drug interactions with human tissue, bioprinting can streamline the path from lab to market.

article thumbnail

Analysis Life Sciences: FDA finalizes new guidance on nonclinical assessment of potential immunotoxicity

Agency IQ

The guidance looks very different from the draft that was published in February 2020, including changes in the scope of the guidance, its sponsorship, and the removal of all mentions of nonhuman primates for animal testing. What are nonclinical studies and when are they conducted in drug development?

FDA 52